Indaba Capital Management, L.P.
Follow13F filer, CIK 1524362, SAN FRANCISCO, CA
Indaba Capital Management, L.P. reported $60,690,926 across 5 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001011438-25-000573
- Period
- 2025-09-30
- Reported value
- $60.7M
- Holdings
- 5
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 6
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ELMEnew | +66,502 | $1.12M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| BLKBexited | -193,000 | -$12.4M |
| BATRKexited | -93,811 | -$4.39M |
| ESPRexited | -3,000,000 | -$2.95M |
| EMBCexited | -221,938 | -$2.15M |
| ADVexited | -980,865 | -$1.29M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2025
Share positions as resolved from 13F-HR 0001011438-25-000573, largest first. % of portfolio is the value over $60,690,926, the sum of the share positions whose value is usable for ratios (method).
Principal amounts
Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).
| Security | Type | Amount | Value | Change |
|---|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRONWOOD PHARMACEUTICALS INC NOTE 1.500% 6/1 | principal | 20,000,000 | $17.8M | +3,000,000 |
| BANDWIDTH INCBANDWIDTH INC NOTE 0.500% 4/0 | principal | 13,000,000 | $11.1M | -27,250,000 |
| SUMMIT HOTEL PPTYSSUMMIT HOTEL PPTYS NOTE 1.500% 2/1 | principal | 6,539,000 | $6.44M | -22,500,000 |
Sold out in Q3 2025
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| TRAVERE THERAPEUTICS INCTRAVERE THERAPEUTICS INC | 13,000,000 | $12.8M | principal |
| BLKBBLACKBAUD INC | 193,000 | $12.4M | shares |
| BATRKATLANTA BRAVES HLDGS INC | 93,811 | $4.39M | shares |
| ESPRESPERION THERAPEUTICS INC NE | 3,000,000 | $2.95M | shares |
| EMBCEMBECTA CORP | 221,938 | $2.15M | shares |
| ADVADVANTAGE SOLUTIONS INC | 980,865 | $1.29M | shares |
How Q3 2025 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001011438-25-000573 | base | 2025-11-14 | acceptance time not in the bulk data set |